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ABSTRACT
Introduction Congenital anomalies (CAs) are a major 
cause of infant mortality, childhood morbidity and long- 
term disability. Over 130 000 children born in Europe every 
year will have a CA. This paper describes the EUROlinkCAT 
study, which is investigating the health and educational 
outcomes of children with CAs for the first 10 years of their 
lives.
Methods and analysis EUROCAT is a European network 
of population- based registries for the epidemiological 
surveillance of CAs. EUROlinkCAT is using the EUROCAT 
infrastructure to support 22 EUROCAT registries in 
14 countries to link their data on births with CAs to 
mortality, hospital discharge, prescription and educational 
databases. Once linked, each registry transforms their 
case data into a common data model (CDM) format and 
they are then supplied with common STATA syntax scripts 
to analyse their data. The resulting aggregate tables 
and analysis results are submitted to a central results 
repository (CRR) and meta- analyses are performed to 
summarise the results across all registries. The CRR 
currently contains data on 155 594 children with a CA 
followed up to age 10 from a population of 6 million births 
from 1995 to 2014.
Ethics The CA registries have the required ethics 
permissions for routine surveillance and transmission 
of anonymised data to the EUROCAT central database. 
Each registry is responsible for applying for and obtaining 
additional ethics and other permissions required for their 
participation in EUROlinkCAT.
Dissemination The CDM and associated documentation, 
including linkage and standardisation procedures, will 
be available post- EUROlinkCAT thus facilitating future 
local, national and European- level analyses to improve 
healthcare. Recommendations to improve the accuracy of 
routinely collected data will be made.
Findings will provide evidence to inform parents, health 
professionals, public health authorities and national 
treatment guidelines to optimise diagnosis, prevention and 
treatment for these children with a view to reducing health 
inequalities in Europe.
INTRODUCTION
Over 130 000 children born in Europe every 
year will have a major congenital anomaly 
(CA), equivalent to 2.5% of all European 
births. CAs include structural defects, chro-
mosomal anomalies and genetic syndromes. 
CAs are a leading cause of perinatal and 
infant mortality, especially in developed 
countries.1 From 2003 to 2012, CAs were asso-
ciated with about 40% of all infant deaths in 
Sweden and England.2 There is a large vari-
ation in child death rates across Europe; in 
2013 the child death rates (age 0–14 years) 
were 60% higher in the UK and Belgium 
compared with Sweden, with an additional 10 
countries being 30% higher than Sweden.3 
Strengths and limitations of this study
 ► The implementation of a common data model en-
ables the same centrally developed syntax script to 
be run in all registries which is efficient and ensures 
standardisation of analysis.
 ► The use of a reference population allows country 
differences to be adjusted for and enables more 
accurate comparisons of the burden of disease 
attributable to congenital anomalies (CAs) across 
countries to be made.
 ► Merging births with CAs to their records in routine 
healthcare data enables a detailed evaluation of the 
accuracy of the data and enables improvements to 
be suggested.
 ► Being unable to share individual case data or aggre-
gate data that might be disclosive reduces the pow-
er of the analysis that can be performed, particularly 
for rare anomalies.
 ► Only specific areas in Europe are represented, with a 
lack of data in particular from Eastern Europe.
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To identify potentially preventable and remedial causes 
it is important to investigate the health inequalities in 
survival in children with CA across Europe.
It has been shown that relying on death certificates as 
a source of information on mortality due to CAs does 
not provide an accurate assessment of the survival for 
children with specific CAs. Death certificates state the 
direct or primary cause of death which may be infection, 
seizures or others and therefore may not mention the 
CA.4 Copeland and Kirby4 concluded that the only way 
to accurately study mortality and survival in children with 
rare CAs is to pool data across CA registries and link these 
to death registries.
Advances in fetal, neonatal and paediatric care have 
improved outcomes for individuals with some CAs, for 
example, Down syndrome (DS)5–7 and cardiac anoma-
lies. Several studies have shown that children with CAs 
account for a very high proportion of all hospital admis-
sions.8 9 However, there is a lack of information on the 
length of hospital stays for children with specific CAs, 
with most studies concerning children with DS, orofacial 
clefts or congenital heart defects (CHD).10 Often hospital 
stays are investigated for the first 2 or 3 years of a child’s 
life.11–14 However, Wehby et al showed that hospital admis-
sions for those born with orofacial clefts were increased 
at all ages up to 60 years of age.15 Rarely has length of 
hospital stay been related to other factors, such as social 
class. Two studies (Derrington 2013 in the USA to 3 years 
of age and Hung 2011 in Taiwan for all ages) both iden-
tified other factors such as ethnicity and socioeconomic 
factors as important influences on the length of inpatient 
stays in children and adults with DS.12 16
The proportion of children born with a CA surviving 
beyond infancy is increasing.5 6 How these children are 
performing in school and their additional educational 
needs is therefore becoming increasingly important 
as there may be a growing population of children and 
young people requiring additional support and resources 
in the future. However, apart from the more common 
genetic syndromes, there is a paucity of information 
about this.17 18 The American Heart Association reviewed 
the literature on children with CHD and concluded that 
they are at an increased risk of developmental delay, even 
once the frequent occurrence of genetic syndromes has 
been taken into account, particularly for neonates or 
infants requiring open heart surgery.19 Wehby et al also 
showed that children with isolated orofacial clefts were 
at a much greater risk of low achievement at school than 
their classmates.20 A systematic review of neurocognitive 
outcomes following general anaesthesia and surgery in 
children concluded that exposure to general anaesthesia 
in young children did affect their development in some 
neurocognitive domains.21 However, the authors recom-
mended that the effects of surgery should be considered 
separately for each specific anomaly.
EUROCAT (https:// eu- rd- platform. jrc. ec. europa. eu/ 
eurocat) is a European network of population- based CA 
registries, which started in 1979 and has expanded to 
include 39 registries in 21 countries covering more than 
29% of European births (1.7 million) per year.22–24 The 
main objectives of EUROCAT are to provide essential 
epidemiological information and surveillance on CAs in 
Europe, to evaluate the effectiveness of primary preven-
tion and to assess the impact of developments in prenatal 
screening.25 26 Hence, the emphasis is on information 
collected up to a baby’s first year of life.
The aim of EUROlinkCAT is to investigate the survival, 
morbidity and educational outcomes of children with 
specific CAs for the first 10 years of their lives by linking 
births with CAs in EUROCAT registries to electronic 
healthcare and education databases. The availability 
of population- based data on births with CAs across the 
EUROCAT network will enable survival, morbidity and 
education to be investigated for specific CAs as well as 
differences in these outcomes across Europe according to 
specific risk factors and social inequalities to be explored.
Electronic healthcare data are increasingly being used 
by researchers to investigate the epidemiology of CAs, 
rather than using information from CA registries. Such 
healthcare data have often been found to be incom-
plete.27–31 A small number of registries will analyse the 
maternal pregnancy records for women registered 
as having had a termination of pregnancy for a fetal 
anomaly (TOPFA) in EUROCAT. This will enable the 
accuracy of routine information on TOPFAs to be evalu-
ated. The accuracy of CA coding in live births will be eval-
uated by comparing the EUROCAT data for live births 
with the CA diagnosis from the electronic healthcare 
databases covering both inpatient and outpatient visits. 
The information on death certificates will be compared 
with the anomalies recorded in EUROCAT. Recommen-
dations will be developed to enable the maximum infor-
mation from electronic healthcare data to be extracted 
for research purposes and to quantify the amount of data 
that cannot be obtained.
This paper describes the design of the study, the 
methods used to obtain and analyse the linked data and 
evaluates the first 3 years’ progress of EUROlinkCAT.
METHODS AND ANALYSIS
Design and setting
In 2017, all EUROCAT registries were invited to partic-
ipate in the EUROlinkCAT study. Twenty- two registries 
from 14 countries agreed to participate and to link all 
live births with a CA registered in their registries and 
born from 1 January 1995 to 31 December 2014. Almost 
all EUROCAT registries send anonymised data on CAs 
occurring in all live births, fetal deaths from 20 weeks 
gestation and TOPFAs to the EUROCAT central data-
base. Comprehensive coding instructions32 and the use of 
the EUROCAT Data Management Programme (EDMP) 
to import data into the central database ensure that stan-
dard variables, definitions and coding are used by all 
registries in the network. CAs are coded locally using the 
WHO International Statistical Classification of Diseases 
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and Related Health Problems (ICD) 9th or 10th Revi-
sion with the British Paediatric Association code exten-
sion offering more specificity (table 1). Cases with minor 
anomalies only are excluded (see EUROCAT Guide 1.4, 
Minor Anomalies for Exclusion (V.14.10.14)). Registries 
can code up to nine anomalies for each case and provide 
additional information in the specified text fields. Based 
on the ICD-9 or ICD-10 codes present, cases are automat-
ically assigned by EDMP to defined major CA subgroups 
in accordance with the EUROCAT Guide 1.4. A case with 
more than one major anomaly may be assigned to more 
than one subgroup. Since 2015, the central database has 
been hosted by the European Commission Joint Research 
Centre in Ispra (Italy).
Tables 1 and 2 provide a list of the 81 EUROlinkCAT 
CA subgroups which include structural anomalies, 
genetic syndromes and chromosomal anomalies that 
will be investigated. There are 60 EUROCAT subgroups 
(table 1) and an additional 21 new CA subgroups not 
defined in EUROCAT (table 2). The subgroups have 
been identified as being reasonably homogeneous to 
provide meaningful information and also to be preva-
lent enough to enable sufficiently precise estimates to be 
obtained from the analyses. For example, the EUROCAT 
subgroup ‘Chromosomal’ was not included as it includes 
all genetic syndromes, but specific syndromes such as DS 
(a EUROCAT subgroup) and Di George syndrome (a 
new subgroup) were included. For some analysis, such 
as mortality, DS children will be analysed according to 
whether they have a cardiac anomaly and/or a gastro-
intestinal anomaly, as these are common and are likely 
to influence their survival. As outcomes are expected 
to be more severe for children with multiple and more 
complex CAs, analyses are also performed separately for 
children with isolated anomalies or with multiple anom-
alies defined according to the methodology by Garne et 
al.33 Isolated anomalies are defined as a CA in one organ 
system only or with a known sequence where multiple CAs 
cascade as a consequence of a single primary anomaly. 
Multiple anomalies are defined as two or more major 
structural CAs in different organ systems, where the 
pattern of anomalies has not been recognised as part of a 
syndrome or sequence.
Linkage
Table 3 provides details of the linkages originally planned 
by the EUROCAT registries and the current linkages 
occurring (as of August 2020). The reasons why some 
registries could not link their data are explored in detail 
in another paper submitted for publication—they include 
not being able to obtain the necessary permissions, rele-
vant outcomes not being recorded in specific data sources 
and the time scale for the data supply being after the end 
of the study’s funding. Currently, 19 registries are linking 
their data to mortality records, 15 plan to link to hospital 
in- patient records and 7 to prescription records for the 
work package that will consider morbidity for children 
born with a CA. At the time of writing, nine registries plan 
to link their information on children with CAs to educa-
tion records. To evaluate the accuracy of the routine 
healthcare data, five registries are additionally linking to 
outpatient data and four will also link to pregnancy infor-
mation recorded in the mother’s health records about 
TOPFAs. The 19 registries survey over 6 million births in 
the population.
For the evaluation of survival and morbidity, each child 
will be followed up for a maximum of 10 years. This age 
cut- off has been chosen to enable enough children to 
be identified and followed up; a longer follow- up would 
mean fewer children would be eligible as currently 
national or local electronic healthcare record sources 
often do not go back more than 10 years. For education 
the maximum follow- up is until the end of compulsory 
school age (typically 16 across participating countries), 
although for some registers data are only available for 
a shorter period of follow- up. The longer follow- up was 
chosen, because in Finland there are no national educa-
tion tests and national data on education attainment are 
available at the age of 15–16 (9th grade).
Reference population
Where possible, each registry obtained information from 
electronic healthcare records, prescription records and 
education records on children without a CA. The defini-
tion of these ‘control’ cohorts will vary according to the 
registry, ranging from all children in the same population 
covered by the registry to a 10% random sample of chil-
dren stratified by birth year and child’s sex. The use of 
such a reference population is essential in interpreting 
differences across countries, as it will provide information 
on key outcomes, such as duration of hospital stays and 
medication prescribing, on children without reported 
anomalies, which is expected to vary by country. Table 4 
provides information on the reference populations being 
identified.
Standardisation and common data models
EUROCAT registries submit 96 core and non- core vari-
ables to the EUROCAT central database providing 
pseudonymised information on the baby and mother, 
diagnosis, karyotype (if known), exposure, family history 
and sociodemographic details. These have already been 
standardised and table 5 lists the 52 variables of which 
34 are core variables and their common coding scheme 
that are used in the EUROlinkCAT study. In contrast, all 
the data obtained from linkage have to be standardised 
to a common format, as the healthcare and educational 
systems across Europe use different native languages and 
coding classification schemes. To do this, each registry 
provided their data dictionaries describing the variables 
in their local databases including the variable names, 
format, definitions and coding schemes.
Table 6 shows how the variable identifying the sex 
(male and female) of the child is coded in the different 
registries with different variable names, different formats 
and different coding schemes. For each substudy in 
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Table 1 EUROCAT congenital anomaly subgroups in EUROlinkCAT
EUROCAT subgroups ICD-10- BPA ICD-9- BPA
All anomalies* Q- chapter, D215, D821, D1810†, P350, 
P351, P371
74, 75, 27910, 2281†, 76076, 76280,
7710, 7711, 77121
Structural anomalies   
  Spina bifida Q05 741
  Hydrocephalus Q03 7423
  Severe microcephaly Q02 7421
  Congenital cataract Q120 74 332
  Congenital heart defects (CHD) Q20–Q26 745, 746, 7470–7474
  Severe CHD Q200, Q201, Q203, Q204, Q212, Q213,
Q220, Q224, Q225, Q226, Q230,
Q232, Q233, Q234, Q251, Q252, Q262
74500, 74510, 7452, 7453, 7456,
7461, 7462, 74600, 7463, 7465,
7466, 7467, 7471, 74720, 74742
  Transposition of great vessels Q203 74510
  Ventricular septal defect Q210 7454
  Atrial septal defect (ASD) Q211 7455
  Atrialventricular septal defect 
(AVSD)
Q212 7456
  Tetralogy of Fallot Q213 7452
  Pulmonary valve stenosis Q221 74601
  Aortic valve atresia/stenosis Q230 7463
  Mitral valve anomalies Q232, Q233 7465, 7466
  Hypoplastic left heart Q234 7467
  Coarctation of aorta Q251 7471
  Patent ductus arteriosus (PDA) as 
only CHD in term infants (GA+37 
weeks)
Q250 7470
  Cystic adenomatous 
malformation of lung
Q3380 No code
  Cleft lip with or without cleft 
palate
Q36, Q37 7491, 7492
  Cleft palate Q35 7490
  Oesophageal atresia with/without 
trachea- oesophageal fistula
Q390–Q391 75030–75031
  Duodenal atresia or stenosis Q410 75110
  Atresia or stenosis of other parts 
of small intestine
Q411–Q418 75111–75112
  Ano- rectal atresia and stenosis Q420–Q423 75 21–75124
  Diaphragmatic hernia Q790 75661
  Gastroschisis Q793 75671
  Omphalocele Q792 75670
  Multicystic renal dysplasia Q6140, Q6141 75316
  Congenital hydronephrosis Q620 75320
  Hypospadias Q54 75260
  Limb reduction defects Q71- Q73 7552–7554
  Craniosynostosis Q750 75600
Chromosomal anomalies   
  Down syndrome Q90 7580
  Trisomy 13 Q914–Q917 7581
Continued
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EUROlinkCAT, a common data model (CDM) containing 
all variables required for its analyses were developed. All 
the EUROlinkCAT CDMs contain the variable L_CH_
SEX, defined as ‘sex of child’ and with a coding scheme 
in integer format of 1=male, 2=female, 3=indeterminate, 
9=not known ‘.’=not recorded or not available for study. 
Ulster University (UU) used the information in each 
registry’s data dictionary to create the new EUROlinkCAT 
‘standardised’ L_CH_SEX variable. UU, in collaboration 
with the registries, created registry- specific syntax scripts 
to standardise all the variables in the EUROlinkCAT 
CDMs. Online supplemental appendices 1–2 list all the 
variables included in the substudies (mortality, electronic 
healthcare records and prescription records).
The CDMs also specify how the data are stored. For 
mortality, all the relevant variables occur only once for 
each EUROCAT case and are stored in the same data file 
(or table) (figure 1). However, when analysing hospital 
admissions, each child may have more than one admission 
and for each admission may receive more than one diag-
nosis. Therefore, the hospital admissions data are stored 
in a separate data file (or table) from the diagnoses data 
and separately from the EUROCAT data on the child; 
each data file contains a reference key which serves to 
link all records belonging to one person for analysis (see 
figure 2). The standardisation syntax scripts from UU 
specify the separate data files (or tables) for each linkage 
containing all the variables in the CDMs.
EUROCAT subgroups ICD-10- BPA ICD-9- BPA
  Trisomy 18 Q910- Q913 7582
  Turner syndrome Q96 75860, 75861, 75862, 75869
  Klinefelter syndrome Q980–Q984 7587
Rare structural anomalies with a EUROCAT subgroup




  Anophthalmos/microphthalmos Q110, Q111, Q112 7430, 7431
  Anophthalmos Q110, Q111 7430
  Congenital glaucoma Q150 74320
  Anotia Q160 74401
  Common arterial truncus Q200 74500
  Double outlet right ventricle Q201 No code
  Single ventricle Q204 7453
  Triscuspid atresia and stenosis Q224 7461
  Ebstein’s anomaly Q225 7462
  Pulmonary valve atresia Q220 74600
  Hypoplastic right heart Q226 No code
  Aortic atresia/interrupted aortic 
arch
Q252 74720
  Total anomalous pulmonary 
venous return
Q262 74742
  Choanal atresia Q300 7480
  Hirschsprung’s disease Q431 75130–75133
  Atresia of bile ducts Q442 75165
  Annular pancreas Q451 75172
  Indeterminate sex Q56 7527
  Situs inversus Q893 7593
  VATER/VACTERL Q8726 759895
*All anomalies=all cases of congenital anomaly, excluding cases with only minor anomalies as defined in Section 3.2 in EUROCAT Guide 1.4 
for cases born post-2005. Cases with more than one anomaly are only counted once in the ‘all Anomalies’ subgroup.
†ICD10 code D1810 (ICD9 code 2281) is the code for cystic hygroma.
GA, gestational age; ICD-9- BPA, International Statistical Classification of Diseases and Related Health Problems 9th Revision with the British 
Paediatric Association; ICD-10- BPA, International Statistical Classification of Diseases and Related Health Problems 10th Revision with the 
British Paediatric Association.
Table 1 Continued
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UU included validation routines in the syntax scripts to 
determine if the data have been correctly transformed. 
For example, it is checked that a date of death does not 
occur prior to the date of birth; while the primary purpose 
is to ensure the data have been standardised correctly, it 
can also reveal any errors in the linked data.
A CDM is not being defined for the linked educa-
tion data as there is limited scope for comparison and 
pooling of data across countries. This is due in part 
to inherent differences in the educational stages and 
systems, the variability in data available, and fewer regis-
tries being able to participate (5 of the registries are 
from England, and 1 from Wales, Denmark, Italy and 
Finland).
Work of the Standardisation Committee
In addition to defining the CDM and its structure, the 
EUROlinkCAT Standardisation Committee was respon-
sible for taking other decisions, usually in consideration 
of local data characteristics, to ensure that data were 
meaningful and comparable across registries. The most 
important issues are listed below:
1. Inclusion according to gestational age (GA) at birth: 
for the mortality study all live births with a GA below 
24 weeks were excluded, as these cases could have 
been miscoded terminations of pregnancy with signs 
of life at birth. However, after running the mortality 
analysis, it was noticed locally that there were survi-
vors in EUROCAT registries at GA 23 weeks. For the 
morbidity studies, the exclusion criterion was low-
ered to be below 23 weeks.
2. Strength of linkage: the success of data linkage de-
pended on the matching method and type of person-
al identifiers used. Where a national unique identifier 
(ID) was available (eg, Denmark, Finland) over 99% 
of cases were matched, but success rates were general-
ly lower when intermediary databases and a combina-
tion of other identifiers (eg, names, postcodes) were 
required to establish a match, particularly if these 
were incomplete or incorrect. A standard way of eval-
uating confidence in a match had to be developed 
so that decisions on inclusion for analyses could be 
consistently made, in order to avoid bias.
3. GA groups: the GA at birth was categorised into <28 
weeks, 28–31 weeks, 32–36 weeks and ≥37 weeks when 
analysing survival, but due to small numbers of survi-
vors at under 28 weeks gestation, the two lowest GA 
categories were combined to <32 weeks.
4. Birth weight: birth weight was categorised into very 
low birth weight ‘<1500 g’, low birth weight ‘≥1500 g 
to <2500 g’, normal birth weight ‘≥2500 g to <4000 
g’ and high birth weight ‘≥4000 g’. Births <1000 g 
were not distinguished from those between 1000 and 
1499 g as there were too few cases for the data to be 
analysed accurately.
5. Singletons versus multiples: there is uncertainty about 
whether the survival in twins with CAs is lower than 
that in singletons.34–37 Hence, all survival analyses 
were performed on singletons alone and then mul-
tiples and singletons combined (multiples were not 
analysed alone as for many registries small numbers 
would limit the analyses that could be performed). 
This enables the survival of singletons and multiples 
in children with CAs to be analysed in detail. When 
examining morbidity, multiplicity was treated as one 
of the risk factors for increased risk of hospitalisa-
tions and lengths of stay to enable any association to 
be analysed, but with less detail than for survival. The 
majority of analyses included singletons and multi-
ples combined.
6. Prenatal diagnoses: the GA at prenatal diagnoses was 
categorised into <22 weeks, 22–31 weeks, ≥32 weeks, 
GA not known and no prenatal diagnosis. For Finland, 
Table 2 New congenital anomaly subgroups in 
EUROlinkCAT
New subgroups for 
EUROlinkCAT ICD-10- BPA ICD-9- BPA
Structural anomalies
  Anomalies of corpus callosum Q040 74221
  Anomalies of intestinal fixation Q433 7514
  Unilateral renal agenesis Q600 No code
  Accessory kidney Q630 75330
  Bladder exstrophy Q641 7535
  Epispadia Q640 75261
  Posterior urethral valves Q6420 75360
  Prune Belly Q794 75672




  Di George syndrome D821 27910
  Goldenhar syndrome Q8704 75606
  Cornelia de Lange syndrome Q8712 759821
  Noonan syndrome Q8714 759896
  Prader- Willi Q8715 759872
  Beckwith- Wiedemann 
syndrome
Q8730 759874
  Williams syndrome Q8784 No code
  Angelman syndrome Q8785 No code
Chromosomal anomalies
  Wolff- Hirschhorn syndrome Q933 75832
  Cri- du chat syndrome Q934 75831
  Karyotype XXX Q970 75885
Sequences
  Pierre- Robin sequence Q8708 75603
ICD-9- BPA, International Statistical Classification of Diseases and 
Related Health Problems 9th Revision with the British Paediatric 
Association; ICD-10- BPA, International Statistical Classification 
of Diseases and Related Health Problems 10th Revision with the 
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the GA was often not recorded, only the trimester of 
diagnoses. Finland’s first trimester diagnoses (week 
0 to week 12) mapped exactly to the EUROlinkCAT 
<22 weeks category. It was decided that Finland’s sec-
ond trimester (week 13 to week 27) diagnoses were 
assumed to occur at 22–31 weeks and third trimester 
(week 28 onwards) diagnoses occurred at ≥32 weeks. 
These assumptions were also checked based on the 
distribution of those cases in Finland with a ‘known’ 
age at discovery and the assumptions held.
7. Length of stay (LOS): the LOS of the child in hospi-
tal was calculated after excluding the stay associated 
with the birth. Methods of identifying the birth stay 
varied in different countries. For hospital admissions 
where admission and discharge occurred on the 
same day, the LOS was considered to be 0.5 days. If an 
admission record was missing a discharge date, then 
discharge date=date of admission+2×(date of latest 
Table 4 Use of a reference population in morbidity and 
education analyses
Congenital anomaly registry Reference population
Croatia: Zagreb Sample of children
Denmark: Funen Whole population
Finland Whole population
France: Île de la Réunion Not provided
Italy: Emilia Romagna Whole population
Italy: Tuscany 10% of population
Netherlands: Northern 10% of population
Portugal: South Sample of children
Spain: Basque Not provided
Spain: Valencian Region Whole population
UK: East Midlands and South 
Yorkshire
Aggregate data from 
population for morbidity 
and population sample for 
education
UK: Northern England Aggregate data from 
population for morbidity 
and population sample for 
education
UK: South West England Aggregate data from 
population for morbidity 
and population sample for 
education
UK: Thames Valley Aggregate data from 
population for morbidity 
and population sample for 
education
UK: Wales Whole population
UK: Wessex Aggregate data from 
population for morbidity 
and population sample for 
education
Ukraine: West No longer in morbidity study
Table 5 Standardised variables from the EUROCAT 
database
EDMP variables used (core variables are shaded in blue)
Baby and mother
1 CENTRE Centre number
2 NUMLOC Local ID of case
3 BIRTH_DATE Date of birth
4 SEX Sex
5 NBRBABY Number of babies delivered
6 SP_TWIN Specify twin type of birth, like or 
unlike, zygosity
7 NBRMALF Number of malformed in multiple 
set
8 TYPE Type of birth
9 CIVREG Civil registration status
10 WEIGHT Birth weight
11 GESTLENGTH Length of gestation in completed 
weeks
12 SURVIVAL Survival beyond 1 week of age
13 DEATH_DATE Date of death
14 DATEMO Date of birth of mother
15 AGEMO Age of mother at delivery
16 BMI Maternal body mass index
17 RESIDMO Mother’s residence code
Diagnosis
19 WHENDISC When discovered
20 CONDISC Condition at discovery
21 AGEDISC If prenatally diagnosed, gestational 
age at discovery
22 FIRST PRE First positive prenatal test
24 KARYO Karyotype of infant/fetus
25 SP_KARYO Specify karyotype
26* GENTEST Genetic test
27* SP_GENTEST Specify genetic test
28 PM Postmortem examination
29 SURGERY First surgery for malformation 
performed or planned
30 SYNDROME Syndrome
31 SP_SYNDROME Specify syndrome
32 MALFO1 Malformation
33 SP_MALFO1 Specify malformation
34 MALFO2 As MALFO1
35 SP_MALFO2 Specify malformation
36 MALFO3 As MALFO1
37 SP_MALFO3 Specify malformation
38 MALFO4 As MALFO1
39 SP_MALFO4 Specify malformation
40 MALFO5 As MALFO1
41 SP_MALFO5 Specify malformation
42 MALFO6 As MALFO1
43 SP_MALFO6 Specify malformation
Continued
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procedure–date of admission). The date of discharge 
was set to the date of the child’s 10th birthday or the 
end of the study period if it was after either of these 
two dates.
8. Socioeconomic status (SES): all registries had differ-
ent variables that could be considered to be a measure 
of the mother’s SES. The variables included maternal 
occupation, maternal education and index of mul-
tiple deprivation derived from residential codes at 
birth. Registries were asked to select the variable they 
believed was the most relevant and to recode their 
selected SES proxy variable into three groups of ap-
proximately equal proportion to enable comparing 
between, for example, mothers in the highest group 
to mothers in the lowest group. The effect of SES on 
survival would be analysed using Cox proportional 
hazard models within each registry. However, only 
seven registries were able to provide a proxy SES vari-
able that was reasonably complete for some or all of 
the time period of the study. It was also planned to 
investigate the association between risk factors such 
as birth weight after adjusting for SES, but due to the 
lack of information on SES this was not included in 
further multivariable analyses.
9. Maternal country of birth: it was determined that the 
maternal country of birth variable would be used as 
a proxy for non- European ethnic origin, as we were 
aware that ethnic origin is poorly recorded. However, 
for those registries with reasonably complete data on 
this, almost 100% of children were reported as being 
of European ethnic origin. Therefore, this variable 
was not included in subsequent analyses as the num-
ber of children considered as ‘non- European ethnic 
origin’ was too small to analyse.
10. Cause of death: cause of death based on the death 
certificates was classified for deaths <1 year and for 
1–9 years separately. Death related to preterm birth 
is very common in the first year after birth, but not 
as relevant to children at 1–9 years of age. Injuries 
and poisoning are more common after the first year. 
The main causes of deaths were classified into six 
groups for deaths <1 year and 11 groups for children 
aged 1–9 years. When working with the results tables 
it was clear that many of these classification groups 
included many small numbers and data could not be 
EDMP variables used (core variables are shaded in blue)
44 MALFO7 As MALFO1
45 SP_MALFO7 Specify malformation
46 MALFO8 As MALFO1
47 SP_MALFO8 Specify malformation
57 OMIM OMIM code/type of Mendelian 
inheritance
Exposure and family history
58 ASSCONCEPT Assisted conception (where 
available)
59† OCCUPMO Mother’s occupation at time of 
conception
Sociodemographic
91 MATEDU Maternal education
92* SOCM Socioeconomic status of mother
93 * SOCF Socioeconomic status of father
94 MIGRANT Migrant status
Derived variables
Byear Year of birth
birth_type Live birth, stillbirth, spontaneous 
abortion, TOPFA, not known
definitions of stillbirths and 
spontaneous abortions vary 
between regions.
This variable recodes birth 
type according to EUROCAT’s 
specifications: cases with 
gestational age ≥20 weeks are 
recoded as ‘stillbirths’ (irrespective 
of the local definition of stillbirth/
spontaneous abortion).
casestatus Only cases with casestatus=1 or 2
al1- al114 EUROCAT subgroups: (0=No, 
1=Yes). Based on EUROCAT 
coding in Guide 1.4
mult_malf Algorithm for case classification 
into isolated and multiple 
anomalies
*See work of the Standardisation Committee (viii).
†EUROCAT Guide 1.4 use ISCO-08 classifications.
EDMP, EUROCAT Data Management Programme; TOOPFA, 
termination of pregnancy for a fetal anomaly.
Table 5 Continued Table 6 Coding of male or female of the live births in 




UK: Wales DEC_SEX_CD 1 2
Germany: Saxony- Anhalt EF306 1 2
Finland SUKUP 1 2
Italy: Tuscany SESSO 1 2
France: Île de la Réunion SexeDefunt 1 2
France: Paris SexeDefunt 1 2
Netherlands: Northern geslacht 1 2
Croatia: Zagreb GENDER M or 1 F or 2
Ukraine: West CH_SEX 1 2
Belgium: Antwerp SEX 1 2
Norway KJONN 1 2
UK: England sex 1 2
Spain: Basque Country SEXO 1 6
Spain: Valencian Region SEXO 1 6
Malta gender M F
Italy: Emilia Romagna SEX M F
Denmark: Funen C_SEX M K
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extracted from the databases. For some registries it 
was only possible to give cause of death as either ‘con-
genital anomaly’ or else ‘any other cause of death’.
11. Surgery: a number of different coding systems were 
used across registries to code surgeries and other pro-
cedures (eg, NCSP by NOMESCO, ICD-9- CM, OPCS-
4). Frequency lists for all codes describing surgeries 
and other procedures were obtained from the linked 
datasets. Two paediatricians then independently de-
termined if a code was a surgery or for another proce-
dure and then a consensus between the two clinicians 
was reached over codes classified as codes for surger-
ies. Further subdivision into anomaly- specific surger-
ies was carried out for anomalies for which specific 
surgeries could be identified that would be expected 
to be performed on these children.
12. Intensive care: it was planned to analyse the number 
of days in intensive care, however, only five registries 
could provide this. Therefore, only whether a child 
had ever been admitted to intensive care was analysed 
rather than their LOS.
13. Ventilation: it was planned to analyse the number of 
days on ventilation. However, as it was decided that 
the LOS in intensive care was not going to be anal-
ysed, the same decision was made for ventilation and 
only whether a child had ever been on ventilation was 
analysed.
Figure 1 Structure of mortality and EUROCAT data used for analysing children’s survival.
Figure 2 Structure of hospital admissions, prescription data and EUROCAT data used for analysing children’s morbidity. ATC 
code, Anatomical Therapeutic Chemical Classification System code; ICU, intensive care unit.
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Assessment of quality of linkage and quality of linked data
Many registries linked their data to National Vital Statis-
tics, which are databases that record all live births with 
follow- up until the child dies or emigrates outside the 
country/region of interest. Therefore, for these regis-
tries for the survival analysis, any child whose record was 
not in the National Vital Statistics Database was judged 
to be a non- match and overall linkage could be assessed. 
Some registries were only able to link to death certificates 
which meant that a non- match, that is, no death certifi-
cate found, was assumed to indicate that the child was still 
alive. The data from these registries were only included in 
the survival analyses if there was additional information 
about the quality of the linkage. For example, in Malta, 
due to the small well- defined population, there was confi-
dence that all deaths had been identified.
In some countries all national databases use the same 
unique ID number (eg, Finland). So, identifying a child 
in the National Vital Statistics meant that there was 
confidence that any hospital stays up to 10 years of age 
would also be identified. For other registries, as not all 
children were likely to be admitted to hospital, each case 
was searched for in, not only the in- patient hospital data-
base (which included the mother’s visit for the birth), but 
also any other healthcare databases (such as outpatient, 
primary- care or prescription databases) for longer than 
the 10 years of follow- up in the study. The lack of infor-
mation in any healthcare database was judged to mean a 
non- match. Sensitivity analysis was performed to assess if 
there were differences in results if the non- matches were 
included.
For the education data, all children known to be alive 
were assumed to be included in the National Educa-
tion Databases and therefore any case not identified was 
assumed to be a non- match.
Syntax scripts were developed centrally by St George’s, 
University of London (SGUL) to evaluate the accuracy 
of the linkage and identify any factors leading to missed 
links (eg, deaths within the first week of life). For each 
registry, the proportion of births in any single year of 
data that have not been linked is calculated and the data 
from any year with less than 85% of cases linked will be 
excluded from further analyses. Second, the quality of 
linked data items was also evaluated: a variable that was 
>20% missing in a year would be excluded from any anal-
ysis in which it featured; and variables that were recorded 
by both the CA registry and the linked database would 
be compared for agreement, by year. In general, it was 
found that data quality was poorer in the earlier years and 
tended to improve over time; however, if data quality fluc-
tuated across the years, then only the longest consecutive 
period where quality was above the threshold would be 
analysed.
Statistical analysis
Protocols and syntax scripts are developed centrally 
to create aggregate data and perform specific analyses 
on the individual cases in each standardised data set in 
STATA (V.13 and upwards). This allows each register to 
submit aggregated data and analytical results (eg, Kaplan- 
Meier estimates, HRs and CIs), rather than individual 
case data, to the EUROlinkCAT central results reposi-
tory (CRR) at UU, UK using a secure web platform. UU 
collates the aggregate data and results and provides these 
data to the researchers responsible for the different anal-
yses and publications. Multi- centre European analyses 
will be performed by combining the individual registries’ 
aggregated data and analytic results, using meta- analytic 
techniques. Additional work is required to develop suit-
able models for combining survival data from several 
registries when the sample sizes are very small as observed 
in many registries.
Small number restrictions (statistical disclosure control)
Four countries have limitations on the release of aggregate 
data and analytic results if the numbers of births involved 
are very small (generally under eight births). This situ-
ation arises in many analyses involving specific CAs, as 
CAs are rare, with some affecting less than 1 in 10 000 
live births. Solutions to enable the maximum amount of 
data to be included in all multi- centre European analyses 
varied according to country. The Northern Netherlands 
released data if all exported results were rounded to the 
nearest 5. Rounding all frequencies ensures that original 
numbers cannot be inferred. For Denmark, a few named 
researchers at SGUL and UU were allowed access to the 
aggregate data for the purpose of collating and including 
in pooled- analysis, on condition that it was securely stored 
and processed; that any individual results involving fewer 
than five people were not released; and that personal 
identification was not possible from any released results. 
The SAIL databank (Wales) provided data to the CRR 
with the requirement that aggregate data on fewer than 
five people were not released and could not be calculated 
from any information in the public domain. The registry 
from Antwerp, Belgium could not release any informa-
tion on three or fewer cases.
Patient and public involvement
A series of focus groups has been held in different Euro-
pean countries involving parents with a child with one 
of four predefined CAs with different health problems 
covering learning difficulties, physical disabilities, visible 
defects and non- visible defects with higher mortality. The 
four anomalies selected were: CHD requiring surgery 
(referred to as severe CHD—a usually non- visible defect 
with high mortality), cleft lip (a visible defect often with 
speech problems), spina bifida (a physical disability with 
associated incontinence problems) and DS (Trisomy 21; 
a visible defect with learning difficulties and often asso-
ciated with CHD). The focus groups have investigated 
parental experiences of having a child with one of the 
above anomalies and assessed parental research priorities 
and a paper will be published in due course.
In addition, a European survey concerning the diag-
nosis, medical care, education and everyday life will be 
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distributed to parents across Europe with children with 
the same four CAs as described above. Registries will 
ensure the questions in the survey are appropriate for 
their country (eg, the provision of health services, given 
how this differs in various European countries) and will 
translate the survey into their native language with back 
translation to confirm the accuracy of the translation. 
The aim is for the survey to be distributed via social media 
by parent support groups across Europe to engage with a 
wide spectrum of parents.
DISCUSSION
The aggregate data and results from the CRR in 
EUROlinkCAT will provide important information on 
the survival, morbidity and education of children born 
with a CA in Europe. Researchers in each CA registry will 
be encouraged to also perform specific local analysis, 
in order to fully exploit the research potential of linked 
datasets. The establishment of a method of standardising 
data from each registry linkage into a CDM provides valu-
able infrastructure enabling future multi- national studies 
to be performed in an efficient manner and new regis-
tries to become involved.
The strength of this study is that the researchers are 
a multidisciplinary group, many of whom have collabo-
rated successfully for many years through being members 
of EUROCAT. In addition, EUROlinkCAT is able to build 
on all the standardisation procedures already established 
in EUROCAT. The implementation of a CDM enables 
the same centrally developed syntax script to be run 
in all the different registries which is efficient and also 
ensures standardisation of analysis across the registries. 
The use of a reference population when analysing health-
care data will aid in the identification of the source of 
differences between registries (eg, average LOS in hospi-
tals will differ) and therefore enable us to better quantify 
the burden of disease attributable to CAs in each country. 
Comparisons of the accuracy of healthcare databases with 
respect to recording CA cases will be informative and 
enable improvements in those areas with less accurate 
data. We will also be developing recommendations on 
how to use the available healthcare data in an optimal 
way to provide information on children with CAs in areas 
without active CA registries.
One of the challenges of EUROlinkCAT is the ability of 
the CA registries to link their data to external data sources 
due to different local data information governance issues 
and the availability of suitable electronic healthcare data-
bases. This requires flexibility in including registries in 
only specific subprojects and acceptance that not all 
registries may be able to perform the linkages planned. 
In addition, some registries require support from other 
partners in all aspects of the project, including applying 
for ethics permissions, adapting protocols, standardising 
data and running statistical syntax scripts. The restriction 
of not being able to share individual case data and also 
aggregate data that might be disclosive or identifiable 
means that all analyses must be performed locally using 
a generic modelling strategy. This does limit the use of 
iterative procedures to explore data in detail. The major 
limitation to the study is that only specific areas in Europe 
are represented, with a lack of data in particular from 
Eastern Europe. Interpretation of differences across 
Europe is challenging as it will be essential to interpret 
results in the light of knowledge about the differences in 
healthcare and education practices across Europe.
The EUROlinkCAT project will enable important 
hypotheses concerning the survival, health and educa-
tion of children with CAs in Europe to be investigated. 
The standardised methods and CDMs will all be available 
freely on the EUROlinkCAT website and will be available 
for use in future research projects to benefit from and 
build on this work, so as to enable other multi- centre 
European projects to exploit routine healthcare data 
available in Europe.
ETHICS AND DISSEMINATION
The CA registries have the required ethics permissions 
and procedures for routine surveillance, data collection 
and transmission of anonymised data to the EUROCAT 
central database, according to national guidelines and 
they were required to submit evidence of these permis-
sions to the EUROlinkCAT ethics portfolio. Local regis-
tries follow national legislation as to whether parental 
consent is needed for registration of babies with anom-
alies. Each registry was responsible for applying for and 
obtaining the additional ethics and other permissions (eg, 
data sharing agreements) required to link and analyse 
their data for EUROlinkCAT. This was an extremely 
lengthy process in some countries as the original data 
collection did not include expectation or consent for the 
data to be used in research, and a new legal basis had to be 
established. Additional assurances and procedures were 
adopted by registries (eg, publication of privacy notices) 
to ensure compliance with the General Data Protection 
Regulation which came into force on 25 April 2018 in the 
European Union. A checklist of minimum specifications 
for data storage/backup was completed by each registry. 
Three registries took over 3 years to get the ethics, legal 
basis, data protection, information governance and data 
sharing agreements in place. UU obtained ethics permis-
sion for the CRR.
Each registry participating in the focus groups with 
parents was responsible for ensuring the correct ethics 
approvals were in place. Similarly, the registries partici-
pating in the dissemination of the parents’ survey will be 
responsible for ensuring the necessary ethics permissions 
are obtained.
An Ethics and Data Protection Advisory Board consisting 
of three independent advisors with the relevant expertise 
monitor all ethical considerations in this project.
The CRR will be used for multiple studies and the 
results from these will be disseminated in peer reviewed 
papers and conference presentations. It is hoped that the 
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experience gained with distributing the parents’ survey 
using parent support groups and social media will also 
lead to development of a framework to enable dissem-
ination of results to be made more directly to parents. 
In addition, a series of reports will be written including 
recommendations for improving the collection and 
analysis of data on CAs in routinely collected data in the 
healthcare databases.
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